Ginkgo Bioworks Holdings, Inc. (DNA) closed the latest trading day at $7.27, indicating a +1.39% change from the previous session's end. The stock exceeded the S&P 500, which registered a gain of 0.08% for the day. On the other hand, the Dow registered a gain of 0.08%, and the technology-centric Nasdaq increased by 0.52%.Coming into today, shares of the company had lost 37.27% in the past month. In that same time, the Medical sector lost 1.03%, while the S&P 500 lost 7.33%.Investors will be eagerly watching ...

Ginkgo Bioworks Holdings, Inc. (DNA) has been beaten down lately with too much selling pressure. While the stock has lost 52.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum ...

Welcome back to TechCrunch Mobility — your central hub for news and insights on the future of transportation. Sign up here for free — just click TechCrunch Mobility!TechCrunch’s transportation team — well at least myself and senior reporter Rebecca Bellan — are hittin’ the road. Destination: SXSW, the annual tech, music, film, and culture conference in Austin. We both have panels and if you’re at SXSW, please come check these out and introduce yourself.  We’ll be keeping our eyes and ears open for transpor ...

Core Viewpoint - Ginkgo Bioworks Holdings, Inc. (DNA) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the changing earnings picture of a company, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - Ginkgo Bioworks is projected to earn -$5.06 per share for the fiscal year ending December 2025, reflecting a 51.2% change from the previous year's reported number [9]. - Over the past three months, the Zacks Consensus Estimate for Ginkgo Bioworks has increased by 17.7%, indicating a positive trend in earnings estimates [9]. Impact of Institutional Investors - Changes in earnings estimates are strongly correlated with stock price movements, largely due to institutional investors who adjust their valuations based on these estimates [5]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, which subsequently affects stock prices [5]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Ginkgo Bioworks to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [11].

-          EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe-          EffiX™ delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNAHANGZHOU, China, March 3, 2025 ...

Ginkgo Bioworks (NYSE: DNA ) remains focused on reducing cash burn and made significant progress in this area in the fourth quarter of 2024. While this is a positive, Ginkgo lacks direction, and its newer Cell Engineering offerings have demonstrated limitedRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by ident ...

Grow with Ginkgo Q4 and FY 2024 Update & Business Review February 25, 2025 Property of Ginkgo Bioworks — 1 Q1 2024 UPDATE & BUSINESS REVIEW Disclaimer FORWARD-LOOKING STATEMENTS This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, incl ...

Financial Data and Key Metrics Changes - Ginkgo Bioworks ended Q4 2024 with $562 million in cash and no bank debt, significantly reducing cash burn to $55 million from $114 million in Q3 2024 [10][32][48] - Total company adjusted EBITDA for Q4 was negative $57 million, an improvement from negative $101 million in Q4 2023, with full-year adjusted EBITDA at negative $293 million, up from negative $365 million in 2023 [30][31][32] Business Line Data and Key Metrics Changes - Cell Engineering revenue reached $35 million in Q4 2024, a 29% increase year-over-year, with full-year revenue at $174 million, down 10% from 2023 when excluding a one-time noncash revenue impact [15][17] - Biosecurity revenue was $9 million in Q4 2024, down from $53 million in 2023, reflecting a 51% decline due to the end of K-12 COVID testing contracts [23][24] Market Data and Key Metrics Changes - The company reported a total of 138 active programs across 85 customers in the Cell Engineering platform, a 5% increase year-over-year [17] - The government segment has been a strong source of growth, although uncertainties in this area are factored into revenue guidance [38][40] Company Strategy and Development Direction - Ginkgo aims to reach adjusted EBITDA breakeven by mid-2026 while maintaining a cash margin of safety, focusing on cost reductions and expanding revenue sources [10][43] - The company is expanding into life science tools and services, responding to market trends in biopharma for more data to support AI models [44][65] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging biotech R&D market but expressed optimism about the potential of new tools offerings and the government segment [38][39] - The company is taking a conservative approach to revenue guidance for 2025, estimating Cell Engineering revenue between $110 million and $130 million and Biosecurity revenue at least $50 million [39][40] Other Important Information - Ginkgo has remediated its SOX material weakness, indicating improved financial reporting processes [43] - The company has achieved a $190 million annualized run rate reduction in spending compared to Q1 2024 [47] Q&A Session Summary Question: What are the ideal customer personas Ginkgo needs to close for new client acquisition? - The ideal customer persona varies by product; for solutions deals, it is typically the head of R&D in large biopharma or the CEO in small biotechs. For data points, it is usually a lead for a drug program, and for automation, it is automation leads responsible for building out new setups [88][90][91]

Financial Data and Key Metrics Changes - The company ended Q4 2024 with $562 million in cash and no bank debt, significantly exceeding its original cost-cutting target for 2024 [10][48] - Total company adjusted EBITDA in Q4 was negative $57 million, an improvement from negative $101 million in Q4 2023 [30] - Cash burn in Q4 2024 was $55 million, down from $114 million in Q3 2024, reflecting successful restructuring efforts [32][33] Business Line Data and Key Metrics Changes - Cell Engineering revenue for Q4 2024 was $35 million, up 29% year-over-year, driven by growth with large biopharma customers [15] - Biosecurity revenue in Q4 2024 was $9 million, with a full-year revenue of $53 million, down 51% from $108 million in 2023 due to the end of K-12 COVID testing contracts [23][24] - The company supported 138 active programs across 85 customers on the Cell Engineering platform in Q4 2024, a 5% increase in active programs year-over-year [17] Market Data and Key Metrics Changes - The government segment has been a source of growth, but uncertainties in this area are factored into the low end of revenue guidance for 2025 [38] - The company expects Cell Engineering revenue for 2025 to be in the range of $110 million to $130 million, with Biosecurity revenue guidance at least $50 million [39][40] Company Strategy and Development Direction - The company aims to reach adjusted EBITDA breakeven while maintaining a cash margin of safety, focusing on cost reduction and revenue expansion [10][12] - Ginkgo is expanding into life science tools and services, responding to market trends in biopharma for more data for AI models [44][46] - The company has achieved a $190 million annualized run rate reduction in spending through Q4 2024, exceeding initial targets [47] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the uncertain macro environment but is encouraged by early traction in tools offerings and the restructuring progress [42][43] - The company is optimistic about its competitive position in the biotech industry and plans to continue reducing cash burn while expanding revenue sources [48][50] - Management emphasizes the importance of maintaining a cash margin of safety to avoid dilutive fundraising [11][48] Other Important Information - The company has remediated its SOX material weakness, indicating improved financial reporting processes [43] - Ginkgo is leading an international consortium for a project worth up to EUR 24 million focused on point-of-care sequencing and metagenomic NGS [83][84] Q&A Session Summary Question: What are the ideal customer personas Ginkgo needs to close for new client acquisition - The ideal customer persona varies by product; for solutions deals, it is typically the head of R&D in large biopharma or the CEO in small biotech [89] - For data points, the target is usually a lead for a drug program, which allows for a wider engagement [90] - For automation, the focus is on automation leads responsible for building out new work cells [91]

Business Segments and Services - Ginkgo Bioworks operates in two business segments: cell engineering and biosecurity, focusing on biological R&D services for various industries[19]. - In 2024, Ginkgo expanded its service offerings to include cell engineering tools, enhancing customer resources for in-house R&D[21]. - The company provides end-to-end cell engineering solutions across multiple markets, including pharmaceuticals, agriculture, and industrial biotechnology[35]. - Ginkgo's services support the development of new therapeutics, vaccines, and agricultural products, addressing urgent global needs[36][40]. - Ginkgo's biosecurity services have evolved to include two core offerings, enhancing detection capabilities and insights into biological threats[29]. - The company partners with government agencies to enhance national security and public health through biological capabilities[45]. - Ginkgo's genetic medicine services include gene therapy, cell therapy, and RNA therapeutics, optimizing manufacturing processes at scale[48]. Technology and Innovation - The company utilizes proprietary automation technologies and AI tools to enhance R&D efficiency and product development[40]. - The EncapS platform improves production strain productivity by 10-30% through ultra-high throughput screening of over 1 million variants[50]. - The company has a metagenomic library of over 2.7 billion genes, facilitating the discovery and optimization of plant traits[54]. - The company offers pilot fermentation capacities ranging from 5 to 3,000 liters for bioprocess development and scale-up[58]. - The introduction of Reconfigurable Automation Cart systems enhances high throughput experimentation for biological workflows[61]. - Ginkgo's Foundry enables high-throughput cell programming, while the Codebase includes reusable biological assets[117]. - The company entered a strategic partnership with Google Cloud in August 2023 to develop AI tools for biology and biosecurity, focusing on large language models to accelerate innovation in various fields[199]. Financial Performance and Revenue - The company reported a net loss attributable to stockholders of approximately $2.1 billion, $892.9 million, and $547.0 million for the fiscal years ended December 31, 2022, 2023, and 2024, respectively[149]. - As of December 31, 2024, the company had an accumulated deficit of approximately $5.8 billion[150]. - The company generates revenue through service fees for Foundry services, which include fixed fees and milestone-based payments[80]. - Ginkgo has transitioned its Biosecurity business to focus on scalable infrastructure, with recurring revenue models for Canopy program services, data, and analytics[85]. - The company expects downstream value share to contribute significantly to income as more programs are added, enhancing overall margins and cash flow[83]. - The company has historically derived a significant portion of its revenues from fees and milestone payments from technical development services, which have not been sufficient to cover full operational costs[150]. Workforce and Organizational Changes - As of December 31, 2024, Ginkgo had 834 employees, reflecting a commitment to a talented and multidisciplinary workforce[98]. - Ginkgo's restructuring in 2024 involved a reduction of over 40% of its workforce, yet the company continued to execute on programs and launch new products[100]. - The company has implemented a restructuring plan aimed at reducing operational expenditures, with workforce reductions starting in June 2024 and expected to be completed by 2025, incurring estimated costs between $20.0 million and $23.0 million[204]. Risks and Challenges - The company may need substantial additional capital in the future to fund its business and has no current commitments for future funding[152][153]. - The company faces risks related to maintaining and expanding customer partnerships, which are critical for generating revenue from cell engineering solutions[164]. - The company has experienced significant organizational changes, which could adversely affect its business and financial condition if not managed effectively[155]. - The company’s ability to commercialize Biosecurity offerings is subject to available government and private funding, which may limit growth opportunities[162]. - The company is exposed to macroeconomic pressures, including inflation and supply chain disruptions, which could lead to higher costs for lab materials and services[180]. - The company may not achieve key program milestones on expected timelines, which could negatively impact its business and stock price[178]. - The company relies on a limited number of suppliers for critical lab supplies, which exposes it to risks related to supply disruptions and increased costs[179]. - The company may face challenges in completing future strategic acquisitions or successfully integrating them, which could adversely affect its business and financial condition[172]. - The company has made past acquisitions that were dilutive to stockholders, and future acquisitions may also have adverse impacts if unsuccessful[173]. - The company is exposed to risks if customers choose to perform services internally or with other partners, impacting revenue potential[209]. Regulatory and Compliance Issues - Ginkgo's operations are subject to regulations from the FDA, FTC, USDA, DEA, and EPA, which may impact business activities[123]. - The company has acted as a systems integrator for COVID-19 diagnostic tests, which are subject to FDA regulation[125]. - Partner laboratories for COVID-19 testing must comply with CLIA standards, which include quality assurance and personnel requirements[133]. - Compliance with federal, state, and local laws regarding hazardous materials is costly, and non-compliance could lead to fines and operational disruptions[189][192]. - The company is facing potential liabilities and reputational harm due to the risks associated with the use of genetically modified organisms (GMOs) and the complexities of compliance with biosecurity regulations[190][191]. Market Position and Competition - Ginkgo's competitive advantage includes a strong intellectual property portfolio, with a focus on patents that provide value and competitive advantages[112]. - The company faces competition from internal R&D departments of therapeutics companies, which may view Ginkgo as a potential customer rather than a competitor[106]. - The synthetic biology industry is characterized by rapid technological changes, and the company must continuously develop its platform to remain competitive[217]. - The company relies heavily on a limited number of large customers, with three customers representing over 10% of total revenue for the year ended December 31, 2024, indicating a concentration risk[207]. Future Outlook - The company expects operating expenses to either remain consistent or decline in 2025 compared to 2024, reflecting stabilization in operational overhead and restructuring actions[150]. - The company’s long-term objective is to generate free cash flow from the commercialization of programs across various industries, but variability in costs and timelines remains a challenge[158]. - The company’s ability to secure new business is dependent on customers' willingness to invest in R&D, which could be adversely affected by declines in R&D spending[205][206]. - The company’s international operations may operate with a lower margin profile due to potentially higher supplier costs and other expenses associated with international markets[198]. - The company is subject to evolving regulations regarding AI, which could impose significant costs and obligations, impacting its operations and market confidence[201].